Comparative Pharmacology
Head-to-head clinical analysis: CEFTAZIDIME SODIUM IN PLASTIC CONTAINER versus KEFTAB.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFTAZIDIME SODIUM IN PLASTIC CONTAINER versus KEFTAB.
CEFTAZIDIME SODIUM IN PLASTIC CONTAINER vs KEFTAB
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ceftazidime inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP3, inhibiting transpeptidase activity and disrupting peptidoglycan cross-linking, leading to cell lysis and death.
Cephalexin binds to penicillin-binding proteins (PBPs) on the bacterial cell wall, inhibiting transpeptidation and disrupting peptidoglycan cross-linking, leading to cell lysis via autolytic enzymes.
1-2 g IV every 8 hours for pseudomonal infections; 500 mg to 1 g IV every 8-12 hours for uncomplicated UTIs.
Cefuroxime axetil (KEFTAB) 250-500 mg orally twice daily for 7-10 days. For uncomplicated urinary tract infections: 250 mg twice daily; for acute otitis media: 500 mg twice daily.
None Documented
None Documented
1.5–2.0 hours in normal renal function; prolonged to 15–30 hours in ESRD.
0.8-1.2 hours (prolonged to 6-8 hours in renal impairment; requires dose adjustment for CrCl <50 mL/min)
Primarily renal (80–90% unchanged via glomerular filtration); biliary/fecal <1%.
Renal: 90-95% unchanged via glomerular filtration and tubular secretion; biliary/fecal: <5%
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic